SEOVF (Sernova Biotherapeutics) Current Accrued Expense: $0.82 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SEOVF Sernova Biotherapeutics Inc SEOVF
29 GF Score
Price $0.10
! 2 Warning Signs
View Full Analysis

What is Sernova Biotherapeutics Current Accrued Expense?

Sernova Biotherapeutics SEOVF -0.47% 29 Current Accrued Expense is $0.82 Mil as of Apr. 2026. GuruFocus rates SEOVF with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Sernova Biotherapeutics's Current Accrued Expense for the quarter that ended in Apr. 2026 was $0.82 Mil.

Sernova Biotherapeutics's quarterly Current Accrued Expense declined from Oct. 2025 ($1.35 Mil) to Jan. 2026 ($1.04 Mil) and declined from Jan. 2026 ($1.04 Mil) to Apr. 2026 ($0.82 Mil).

Sernova Biotherapeutics's annual Current Accrued Expense declined from Oct. 2023 ($1.35 Mil) to Oct. 2024 ($1.27 Mil) but then increased from Oct. 2024 ($1.27 Mil) to Oct. 2025 ($1.35 Mil).

Sernova Biotherapeutics Current Accrued Expense Related Terms

Sernova Biotherapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Sernova Biotherapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sernova Biotherapeutics Current Accrued Expense Chart

Sernova Biotherapeutics Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.51 1.35 1.27 1.35

Sernova Biotherapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.16 15.09 1.35 1.04 0.82
SEOVF
29GF Score
Sernova Biotherapeutics Inc SEOVF
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sernova Biotherapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.82 Mil mean?
Sernova Biotherapeutics (SEOVF) has a Current Accrued Expense of $0.82 Mil as of Apr. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sernova Biotherapeutics and its competitors.
Is Sernova Biotherapeutics' Current Accrued Expense too high?
Sernova Biotherapeutics' current Current Accrued Expense is $0.82 Mil. Overall, Sernova Biotherapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Sernova Biotherapeutics' Current Accrued Expense compare to VRTX and REGN?
Sernova Biotherapeutics' Current Accrued Expense of $0.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sernova Biotherapeutics and its competitors. Sernova Biotherapeutics's current Current Accrued Expense is $0.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sernova Biotherapeutics stock overvalued right now?
Sernova Biotherapeutics (SEOVF) has a current Current Accrued Expense of $0.82 Mil. The current Current Accrued Expense is $0.82 Mil. Sernova Biotherapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Sernova Biotherapeutics (SEOVF), the current Current Accrued Expense is $0.82 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sernova Biotherapeutics Business Description

Other Exchanges PSH0:GermanySVA:Canada
Address RPO Central Parkway, PO Box 29592, Mississauga, ON, CAN, L5A 4H2
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
29GF Score

Get the complete analysis for SEOVF

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price